Tags

Type your tag names separated by a space and hit enter

The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gynecol Oncol. 2006 Dec; 103(3):831-40.GO

Abstract

OBJECTIVE

To analyze the expression of phospholipase A2 (PLA2) isoforms and its relationship with matrix metalloproteinase (MMP) expression and clinical parameters in advanced-stage (FIGO III-IV) ovarian carcinoma.

METHODS

Seventy-seven fresh frozen effusions from ovarian carcinoma patients were studied for messenger RNA (mRNA) expression of 10 secretory PLA2 (sPLA2) isoforms (IB, IIA/D/E/F, III, V, X, XII and XIII), the PLA2 receptor (sPLA2R), cytoplasmic PLA2 (cPLA2), PLA2-activating protein (PLAP) and MMP-2 using reverse transcription polymerase chain reaction (RT-PCR). Phosphorylated cPLA2 (p-cPLA2) protein expression was studied in 52 effusions using immunohistochemistry. MMP-2 and MMP-9 activity was evaluated in 22 and 20 effusions, respectively, using zymography. Expression was analyzed for correlation with clinicopathologic parameters, chemotherapy status and survival.

RESULTS

PLA2 isoforms, sPLA2R, PLAP and MMP-2 mRNA was expressed in >95% of specimens. p-cPLA2 protein was expressed in 46/52 (88%) effusions. MMP-2 activity was found in all specimens, while that of MMP-9 was detected in 19/20 effusions. MMP-2 was found to be co-expressed with p-cPLA2 (p=0.003) and sPLA2-IIA (p=0.021). Lower expression of sPLA2-IIA (p<0.001) and higher expression of sPLA2-V (p=0.038) and sPLA2-XIII (p=0.001) was found in post-chemotherapy effusions. In univariate survival analysis, higher levels of sPLA2-V correlated with better overall (OS, p=0.021) and progression-free (PFS, p=0.025) survival. For patients with post-chemotherapy effusions, FIGO stage IV and higher PLAP mRNA expression correlated with worse OS (p=0.005 for both PLAP and stage), while higher PLAP (p=0.025) and sPLA2-XII (p=0.027) levels and FIGO stage IV (p<0.001) correlated with shorter PFS. In Cox multivariate analysis, PLAP expression (p=0.022) and FIGO stage (p=0.036) independently predicted poor OS, while higher sPLA2-XII levels (p=0.04) and FIGO stage (p=0.003) were independent predictors of shorter PFS.

CONCLUSIONS

The present study documents for the first time expression of PLA2 isoforms, sPLA2R and PLAP in ovarian carcinoma. PLA2 isoenzyme expression differs in pre- and post-chemotherapy specimens. PLAP and sPLA2-XII may be independent predictors of poor outcome for patients with post-chemotherapy effusions.

Links

Publisher Full Text

Authors+Show Affiliations

Gorovetz M
Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel, and Department of Gynecologic Oncology, National Hospital-Norwegian Radium Hospital, Oslo, Norway.
Baekelandt M
No affiliation info available
Berner A
No affiliation info available
Trope' CG
No affiliation info available
Davidson B
No affiliation info available
Reich R
No affiliation info available

MeSH

Adenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAscitic FluidCystadenocarcinoma, SerousDNA PrimersDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMatrix Metalloproteinase 2Matrix Metalloproteinase 9Matrix MetalloproteinasesMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialNorwayOvarian NeoplasmsPhospholipasesPrognosisProtein IsoformsReverse Transcriptase Polymerase Chain ReactionSurvival Analysis

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16919315

Citation

Gorovetz, Michal, et al. "The Clinical Role of Phospholipase A2 Isoforms in Advanced-stage Ovarian Carcinoma." Gynecologic Oncology, vol. 103, no. 3, 2006, pp. 831-40.
Gorovetz M, Baekelandt M, Berner A, et al. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol. 2006;103(3):831-40.
Gorovetz, M., Baekelandt, M., Berner, A., Trope', C. G., Davidson, B., & Reich, R. (2006). The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecologic Oncology, 103(3), 831-40.
Gorovetz M, et al. The Clinical Role of Phospholipase A2 Isoforms in Advanced-stage Ovarian Carcinoma. Gynecol Oncol. 2006;103(3):831-40. PubMed PMID: 16919315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. AU - Gorovetz,Michal, AU - Baekelandt,Mark, AU - Berner,Aasmund, AU - Trope',Claes G, AU - Davidson,Ben, AU - Reich,Reuven, Y1 - 2006/08/17/ PY - 2006/03/12/received PY - 2006/06/07/revised PY - 2006/06/22/accepted PY - 2006/8/22/pubmed PY - 2007/1/20/medline PY - 2006/8/22/entrez SP - 831 EP - 40 JF - Gynecologic oncology JO - Gynecol Oncol VL - 103 IS - 3 N2 - OBJECTIVE: To analyze the expression of phospholipase A2 (PLA2) isoforms and its relationship with matrix metalloproteinase (MMP) expression and clinical parameters in advanced-stage (FIGO III-IV) ovarian carcinoma. METHODS: Seventy-seven fresh frozen effusions from ovarian carcinoma patients were studied for messenger RNA (mRNA) expression of 10 secretory PLA2 (sPLA2) isoforms (IB, IIA/D/E/F, III, V, X, XII and XIII), the PLA2 receptor (sPLA2R), cytoplasmic PLA2 (cPLA2), PLA2-activating protein (PLAP) and MMP-2 using reverse transcription polymerase chain reaction (RT-PCR). Phosphorylated cPLA2 (p-cPLA2) protein expression was studied in 52 effusions using immunohistochemistry. MMP-2 and MMP-9 activity was evaluated in 22 and 20 effusions, respectively, using zymography. Expression was analyzed for correlation with clinicopathologic parameters, chemotherapy status and survival. RESULTS: PLA2 isoforms, sPLA2R, PLAP and MMP-2 mRNA was expressed in >95% of specimens. p-cPLA2 protein was expressed in 46/52 (88%) effusions. MMP-2 activity was found in all specimens, while that of MMP-9 was detected in 19/20 effusions. MMP-2 was found to be co-expressed with p-cPLA2 (p=0.003) and sPLA2-IIA (p=0.021). Lower expression of sPLA2-IIA (p<0.001) and higher expression of sPLA2-V (p=0.038) and sPLA2-XIII (p=0.001) was found in post-chemotherapy effusions. In univariate survival analysis, higher levels of sPLA2-V correlated with better overall (OS, p=0.021) and progression-free (PFS, p=0.025) survival. For patients with post-chemotherapy effusions, FIGO stage IV and higher PLAP mRNA expression correlated with worse OS (p=0.005 for both PLAP and stage), while higher PLAP (p=0.025) and sPLA2-XII (p=0.027) levels and FIGO stage IV (p<0.001) correlated with shorter PFS. In Cox multivariate analysis, PLAP expression (p=0.022) and FIGO stage (p=0.036) independently predicted poor OS, while higher sPLA2-XII levels (p=0.04) and FIGO stage (p=0.003) were independent predictors of shorter PFS. CONCLUSIONS: The present study documents for the first time expression of PLA2 isoforms, sPLA2R and PLAP in ovarian carcinoma. PLA2 isoenzyme expression differs in pre- and post-chemotherapy specimens. PLAP and sPLA2-XII may be independent predictors of poor outcome for patients with post-chemotherapy effusions. SN - 0090-8258 UR - https://www.unboundmedicine.com/medline/citation/16919315/The_clinical_role_of_phospholipase_A2_isoforms_in_advanced_stage_ovarian_carcinoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(06)00515-4 DB - PRIME DP - Unbound Medicine ER -